TABLE 10

Products, inhalers and characteristics of LAMA-LABA combination therapies

Assessed by transition dyspnea index (TDI), (c) by St.Georges Respiratory Questionnaire (SGRQ), (d) moderate + severe exacerbations. Prescribing Information: www.accessdata.fda.gov/scripts/cder/daf/ (USA), www.fachinfo.de/(EU, Germany), www.medicines.org.uk/emc/(UK).

Active IngredientIndication (Brand)aInhalerDelivered DosePharmacological ProfileClinical Summary
Aclidinium (bromide) + formoterol (fumarate dihydrate)Maintenance treatment of COPD (not in asthma without ICS)
Duaklir Pressair and generics
Multidose DPI396 μg (acl-br)
+ 11.8 μg (for-fu-hydr)
1 actuation BID
LAMA
and LABA
Airflow, symptoms and dyspnoe(b) improved vs. components, aclidinium component shown to reduce exacerbations(c) vs. pbo
Glycopyrronium (bromide) + formoterol (fumarate dihydrate)Maintenance treatment of COPD (not in asthma without ICS)
Bevespi Aerosphere
pMDI9 μg (gly-br) + 4.8 μg (for-fu-hydr)/puff
2 puffs BID
LAMA
and LABA
Symptom relief and airflow improvement vs. components and pbo, dyspnea,(b) and HRQoL(c) vs. pbo, improvement vs. components (partly trends only)
Glycopyrronium (bromide) + indacaterol (maleate)Maintenance treatment of COPD (not in asthma without ICS) EU: Ultibro Breezhaler USA: Ultibron Neohaler (discontinued)Single dose DPI54 μg (gly-br) + 110 μg (ind-ma)
1 inhalation QD
12.8 µg (gly-br) and 20.8µg (ind-ma) 1 inhalation BID
LAMA
and LABA
Symptom relief and airflow improvement vs. components and tiotropium, dyspnea,(b) and HRQoL(c) improved vs. pbo, tiotropium, and fluticasone/salmeterol, exacerbations(d) reduced vs. glycopyrronium
Tiotropium (bromide) + olodaterol (hydrochloride)Maintenance treatment of COPD (not in asthma without ICS)
Spiolto (Stiolto) Respimat
Multidose SMI2.5 μg (tio) + 2.5 μg (olo)/actuation
2 actuations QD
LAMA
and LABA
Airflow improvement, symptom relief, dyspnea,(b) and HRQoL(c) improvement vs. components, excacerbations(d) vs. tiotropium improved (at significance threshold, tiotropium vs. pbo significant)
Umeclidinium (bromide) + vilanterol (trifenatate)Maintenance treatment of COPD (not in asthma without ICS)
Anoro Ellipta
Multidose DPI (strip package)55 μg (ume) + 22 μg (vil)
1 inhalation QD
LAMA
and LABA
Symptom relief and airflow improvement vs. components and pbo, improvement of dyspnea(b) vs. pbo not components, reduction of exacerbations(d) vs. pbo, not vs. tiotropium
  • aThe brand names are not meant to be an exhaustive list; they are provided for illustrative purposes, as different products containing the same drugs may have different quantitative compositions, formulations, devices, and overall characteristics.

  • pbo, placebo.